Alemtuzumab in the treatment of multiple sclerosis
Óscar Fernandez Institute of Clinical Neuroscience, Neurology Department, Hospital Regional Universitario Carlos Haya, FIMABIS, Malaga, Spain Abstract: Alemtuzumab (formerly known as Campath-1H) has recently been approved by the European Medicines Agency for highly-active, relapsing-rem...
Saved in:
Main Author: | Fernandez Ó |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/74a7d160c74b48a585fc912165f59d34 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emerging therapies for treatment of multiple sclerosis
by: John R Corboy, et al.
Published: (2010) -
Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
by: Slobodan M Jankovic
Published: (2010) -
The effect of smoking on the symptoms and progression of multiple sclerosis: a review
by: Afsaneh Shirani, et al.
Published: (2010) -
Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients [Corrigendum]
by: Taheri M, et al.
Published: (2019) -
Vascular involvement in systemic sclerosis (scleroderma)
by: Pattanaik D, et al.
Published: (2011)